The Food and Drug Administration has extended its time to review Neurocrine Bioscience's application for its sleeping pill Indiplon, but the company reports that it is moving forward with marketing the drug...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99